Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer.

biomarkers breast cancer data science decision theory gene expression mathematical oncology personalized medicine precision medicine receptor status

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
02 Apr 2022
Historique:
received: 17 02 2022
revised: 24 03 2022
accepted: 28 03 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Estrogen and progesterone receptors being present or not represents one of the most important biomarkers for therapy selection in breast cancer patients. Conventional measurement by immunohistochemistry (IHC) involves errors, and numerous attempts have been made to increase precision by additional information from gene expression. This raises the question of how to fuse information, in particular, if there is disagreement. It is the primary domain of Dempster-Shafer decision theory (DST) to deal with contradicting evidence on the same item (here: receptor status), obtained through different techniques. DST is widely used in technical settings, such as self-driving cars and aviation, and is also promising to deliver significant advantages in medicine. Using data from breast cancer patients already presented in previous work, we focus on comparing DST with classical statistics in this work, to pave the way for its application in medicine. First, we explain how DST not only considers probabilities (a single number per sample), but also incorporates uncertainty in a concept of 'evidence' (two numbers per sample). This allows for very powerful displays of patient data in so-called ternary plots, a novel and crucial advantage for medical interpretation. Results are obtained according to conventional statistics (ODDS) and, in parallel, according to DST. Agreement and differences are evaluated, and the particular merits of DST discussed. The presented application demonstrates how decision theory introduces new levels of confidence in diagnoses derived from medical data.

Identifiants

pubmed: 35455687
pii: jpm12040570
doi: 10.3390/jpm12040570
pmc: PMC9028435
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Sci Rep. 2021 Feb 19;11(1):4233
pubmed: 33608588
Clin Cancer Res. 2008 Oct 1;14(19):5959-66
pubmed: 18829474
Genome Biol. 2012 Dec 10;13(12):R112
pubmed: 23228031
J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81
pubmed: 17077359
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Stat Methods Med Res. 2009 Dec;18(6):533-41
pubmed: 20048383
Cancer Inform. 2009;7:57-73
pubmed: 19352459
Nat Rev Genet. 2013 Feb;14(2):89-99
pubmed: 23269463
Cancer Inform. 2012;11:147-56
pubmed: 22872785
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Clin Cancer Res. 2017 Jul 15;23(14):3676-3683
pubmed: 28143867
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
Med Biol Eng Comput. 2012 Sep;50(9):981-90
pubmed: 22622817
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
J Clin Pathol. 2013 Jun;66(6):478-84
pubmed: 23526546
PLoS One. 2016 Jun 07;11(6):e0156594
pubmed: 27272489
BMC Cancer. 2014 Mar 19;14:211
pubmed: 24645668
BMC Med Genomics. 2009 Jul 02;2:40
pubmed: 19573224
BMC Cancer. 2011 Apr 18;11:143
pubmed: 21501481
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Breast Cancer Res. 2015 Apr 23;17:60
pubmed: 25902832
Clin Cancer Res. 2008 Aug 15;14(16):5158-65
pubmed: 18698033
PLoS One. 2016 Feb 19;11(2):e0148957
pubmed: 26895349
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Genome Biol. 2004;5(9):R66
pubmed: 15345050
Nat Biotechnol. 2006 Dec;24(12):1471-2
pubmed: 17160034
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Oncotarget. 2017 Aug 24;8(44):77341-77359
pubmed: 29100391
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Carcinogenesis. 2013 Oct;34(10):2300-8
pubmed: 23740839
Bioinformation. 2006 Jul 19;1(5):170-5
pubmed: 17597882
Biomed Res Int. 2020 Aug 6;2020:1363827
pubmed: 32832541
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
NPJ Breast Cancer. 2016;2:
pubmed: 28691057
PeerJ. 2014 Sep 23;2:e561
pubmed: 25332844
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Breast Cancer Res Treat. 2010 Feb;119(3):685-99
pubmed: 20012355
PLoS One. 2010 Dec 01;5(12):e15031
pubmed: 21152022
Breast Cancer Res. 2008;10(4):R65
pubmed: 18662380
Bioinformatics. 2012 Dec 1;28(23):3153-4
pubmed: 23044545
Breast Cancer Res Treat. 2008 Mar;108(2):191-201
pubmed: 18297396
Nat Rev Clin Oncol. 2011 Dec 06;9(1):48-57
pubmed: 22143140
Lancet Oncol. 2007 Mar;8(3):203-11
pubmed: 17329190
Virchows Arch. 2004 Aug;445(2):119-28
pubmed: 15221370
Clin Cancer Res. 2014 Jan 15;20(2):511-21
pubmed: 24443618
Breast Cancer Res. 2015 Mar 20;17:43
pubmed: 25887482
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
J Clin Oncol. 2013 Aug 1;31(22):2783-90
pubmed: 23816962
Breast Cancer Res Treat. 2018 Nov;172(2):313-326
pubmed: 30117066
BMC Genomics. 2008 Aug 06;9:375
pubmed: 18684329
Am J Clin Pathol. 2011 Jan;135(1):157-62
pubmed: 21173138
J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3
pubmed: 19755043
PLoS One. 2013 Oct 03;8(10):e76421
pubmed: 24098497
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Cancer. 2011 Apr 15;117(8):1575-82
pubmed: 21472705
Stat Appl Genet Mol Biol. 2005;4:Article17
pubmed: 16646834
Cancer Biol Ther. 2015;16(2):317-24
pubmed: 25756514
J Clin Pathol. 2000 Apr;53(4):292-301
pubmed: 10823126
Nat Biotechnol. 2004 Jun;22(6):656-8; author reply 658
pubmed: 15175677
J Oncol Pract. 2010 Jul;6(4):195-7
pubmed: 21037871
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Ann Oncol. 2007 May;18(5):845-50
pubmed: 17351254
NPJ Breast Cancer. 2016 Jun 08;2:16019
pubmed: 28721380
Acta Pharmacol Sin. 2015 Jan;36(1):24-31
pubmed: 25500870
IEEE Trans Syst Man Cybern B Cybern. 2006 Dec;36(6):1395-406
pubmed: 17186815
PLoS Genet. 2007 Sep;3(9):1724-35
pubmed: 17907809
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
J Histochem Cytochem. 2011 Feb;59(2):146-57
pubmed: 21339180
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Pharmacogenomics J. 2010 Aug;10(4):278-91
pubmed: 20676067
Oncotarget. 2015 Nov 3;6(34):36652-74
pubmed: 26474389
J Clin Pathol. 2015 Feb;68(2):93-9
pubmed: 25488926
Biostatistics. 2010 Apr;11(2):242-53
pubmed: 20097884
PLoS One. 2013 Aug 19;8(8):e66848
pubmed: 23990869
Methods Mol Biol. 2006;338:175-90
pubmed: 16888359
Clin Cancer Res. 2011 Sep 15;17(18):6012-20
pubmed: 21807638

Auteurs

Michael Kenn (M)

Section of Biosimulation and Bioinformatics, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

Rudolf Karch (R)

Section of Biosimulation and Bioinformatics, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

Dan Cacsire Castillo-Tong (D)

Translational Gynecology Group, Department of Obstetrics and Gynecology Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Christian F Singer (CF)

Translational Gynecology Group, Department of Obstetrics and Gynecology Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Heinz Koelbl (H)

Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Wolfgang Schreiner (W)

Section of Biosimulation and Bioinformatics, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

Classifications MeSH